Encompass Health (NYSE:EHC) Q1 2024 Results
Main financial results
-
Revenue: USD 1.32 billion (up 13% from Q1 2023).
-
Net profit: USD 113 million (up 28% compared to Q1 2023).
-
Margin: 8.6% (up from 7.6% in Q1 2023). The increase in margin was driven by an increase in revenue.
-
EPS: USD 1.13 (up from USD 0.89 in Q1 2023).
All numbers shown in the chart above are for the trailing 12 month (TTM) period.
Medical revenues and profits exceed expectations
Sales exceeded analysts' expectations by 3.4%. Earnings per share (EPS) also exceeded analyst estimates by 20%.
Looking ahead, revenues are expected to grow by an average of 8.6% over the next three years, compared to a growth forecast of 6.7% for the U.S. healthcare industry.
performance of American healthcare industry.
The company's stock price is almost unchanged from a week ago.
risk analysis
Before you take the next step, you need to know the following: 1 warning sign for Encompass Health What we discovered.
Have feedback on this article? Curious about its content? contact Please contact us directly. Alternatively, email our editorial team at Simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.
